InnoCan Pharma Corporation
INNO
CNSX
| Weiss Ratings | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.11 | |||
| Price History | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 5.26% | |||
| 30-Day Total Return | -2.44% | |||
| 60-Day Total Return | 5.26% | |||
| 90-Day Total Return | -4.76% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -37.50% | |||
| 2-Year Total Return | -18.37% | |||
| 3-Year Total Return | -66.10% | |||
| 5-Year Total Return | 233.33% | |||
| 52-Week High % Change | -40.91% | |||
| 52-Week Low % Change | 21.88% | |||
| Price | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.33 | |||
| 52-Week Low Price | $0.16 | |||
| 52-Week Low Price (Date) | Dec 30, 2024 | |||
| 52-Week High Price (Date) | May 09, 2024 | |||
| Valuation | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 39.36M | |||
| Enterprise Value | 36.20M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -50.51% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.90 | |||
| Price/Book (Q) | 10.83 | |||
| Enterprise Value/Revenue (TTM) | 1.25 | |||
| Price | $0.20 | |||
| Enterprise Value/EBITDA (TTM) | -30.55 | |||
| Enterprise Value/EBIT | -29.63 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 281.64M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 403-777-1519 | |||
| Address | 1015, 926 – 5 Avenue SW Calgary, AB T2P 0N7 | |||
| Website | innocanpharma.com | |||
| Country | Canada | |||
| Year Founded | 2018 | |||
| Profitability | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -4.22% | |||
| Profit Margin | -8.99% | |||
| Management Effectiveness | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -9.28% | |||
| Return on Equity | -- | |||
| Income Statement | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 28.93M | |||
| Total Revenue (TTM) | 28.93M | |||
| Revenue Per Share | $0.10 | |||
| Gross Profit (TTM) | 26.07M | |||
| EBITDA (TTM) | -1.19M | |||
| EBIT (TTM) | -1.22M | |||
| Net Income (TTM) | -2.60M | |||
| Net Income Avl. to Common (TTM) | -2.60M | |||
| Total Revenue Growth (Q YOY) | 111.22% | |||
| Earnings Growth (Q YOY) | 115.54% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 87.18% | |||
| Balance Sheet | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 5.06M | |||
| Cash Per Share (Q) | $0.02 | |||
| Total Current Assets (Q) | 9.48M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 6.94M | |||
| Current Ratio (Q) | 3.572 | |||
| Book Value Per Share (Q) | $0.02 | |||
| Total Assets (Q) | 9.60M | |||
| Total Current Liabilities (Q) | 2.65M | |||
| Total Debt (Q) | 1.00K | |||
| Total Liabilities (Q) | 2.65M | |||
| Total Common Equity (Q) | 5.15M | |||
| Cash Flow | INNO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -20.00K | |||
| Cash from Financing (TTM) | 3.42M | |||
| Net Change in Cash (TTM) | 1.03M | |||
| Levered Free Cash Flow (TTM) | -263.20K | |||
| Cash from Operations (TTM) | -2.39M | |||
